BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/6/2019 11:29:12 AM | Browse: 85 | Download: 32
Publication Name World Journal of Clinical Cases
Manuscript ID 45306
Country of Manuscript Source United States
2019-01-10 01:04
Peer-Review Started
2019-01-10 05:23
To Make the First Decision
2019-02-18 02:58
Return for Revision
2019-03-04 07:05
2019-06-05 14:15
Second Decision
2019-06-10 02:12
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-06-10 22:14
Articles in Press
2019-06-10 22:14
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2019-07-05 09:45
Publish the Manuscript Online
2019-07-06 11:29
ISSN 2307-8960 (online)
Open Access This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Minireviews
Article Title Cholestatic liver diseases: An era of emerging therapies
Manuscript Source Invited Manuscript
All Author List Hrishikesh Samant, David Dies, Hosein Shokouh-Amiri, Gazi Zibari, Moheb Boktor, Wuttiporn Manatsathit and Jonathan Steven Alexander
Author(s) ORCID Number
Hrishikesh Samant http://orcid.org/0000-0002-6401-9267
David Dies http://orcid.org/0000-0002-9230-070X
Hosein Shokouh-Amiri http://orcid.org/0000-0002-0278-377X
Gazi Zibari http://orcid.org/0000-0001-7689-4299
Moheb Boktor http://orcid.org/0000-0002-8652-3878
Wuttiporn Manatsathit http://orcid.org/0000-0003-4406-1588
Jonathan Steven Alexander http://orcid.org/0000-0003-2409-4518
Funding Agency and Grant Number
Corresponding author Jonathan Steven Alexander, FACG, PhD, Professor, Department of Molecular and Cellular Physiology, Louisiana State University, School of Medicine, 1501 Kings Highway, Shreveport, LA71103, United States. jalexa@lsuhsc.edu
Keywords Bile acids; Drug therapy; Cholestatic liver disease; Nuclear receptor agonists
Core Tip Anti-cholestatic therapeutic options now go beyond ursodeoxycholic acid (UDCA) and target nuclear receptors regulating bile acid (farnesoid X receptor) and G protein-coupled receptor and fibroblast growth factor-19. Additionally enterohepatic bile acid transporters and norUDCA represent potential targets in cholestatic disease.
Publish Date 2019-07-06 11:29
Citation Samant H, Manatsathit W, Dies D, Shokouh-Amiri H, Zibari G, Boktor M, Alexander JS. Cholestatic liver diseases: An era of emerging therapies. World J Clin Cases 2019; 7(13): 1571-1581
Url https://www.wjgnet.com/2307-8960/full/v7/i13/1571.htm
DOI https://dx.doi.org/10.12998/wjcc.v7.i13.1571
Full Article (PDF) WJCC-7-1571.pdf
Full Article (Word) WJCC-7-1571.docx
Manuscript File 45306-Review.docx
Answering Reviewers 45306-Answering reviewers.pdf
Audio Core Tip 45306-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 45306-Conflict-of-interest statement.pdf
Copyright License Agreement 45306-Copyright license agreement.pdf
Peer-review Report 45306-Peer-review(s).pdf
Scientific Misconduct Check 45306-Scientific misconduct check.pdf
Scientific Editor Work List 45306-Scientific editor work list.pdf